Literature DB >> 33510227

Decreased angiogenesis as a possible pathomechanism in cervical degenerative myelopathy.

L O Brandenburg1, C A Mueller2, Christian Blume3, M F Geiger2, M Müller4, H Clusmann2, V Mainz5, J Kalder6.   

Abstract

Endogenous immune mediated reactions of inflammation and angiogenesis are components of the spinal cord injury in patients with degenerative cervical myelopathy (DCM). The aim of this study was to identify alteration of certain mediators participating in angiogenetic and inflammatory reactions in patients with DCM. A consecutive series of 42 patients with DCM and indication for surgical decompression were enrolled for the study. 28 DCM patients were included, as CSF samples were taken preoperatively. We enrolled 42 patients requiring surgery for a thoracic abdominal aortic aneurysm (TAAA) as neurologically healthy controls. In 38 TAAA patients, CSF samples were taken prior to surgery and thus included. We evaluated the neurological status of patients and controls prior to surgery including NDI and mJOA. Protein-concentrations of factors with a crucial role in inflammation and angiogenesis were measured in CSF via ELISA testing (pg/ml): Angiopoietin 2, VEGF-A and C, RANTES, IL 1 beta and IL 8. Additionally, evaluated the status of the blood-spinal cord barrier (BSCB) by Reibers´diagnostic in all participants. Groups evidently differed in their neurological status (mJOA: DCM 10.1 ± 3.3, TAAA 17.3 ± 1.2, p < .001; NDI: DCM 47.4 ± 19.7, TAAA 5.3 ± 8.6, p < .001). There were no particular differences in age and gender distribution. However, we detected statistically significant differences in concentrations of mediators between the groups: Angiopoietin 2 (DCM 267.1.4 ± 81.9, TAAA 408.6 ± 177.1, p < .001) and VEGF C (DCM 152.2 ± 96.1, TAAA 222.4 ± 140.3, p = .04). DCM patients presented a mild to moderate BSCB disruption, controls had no signs of impairment. In patients with DCM, we measured decreased concentrations of angiogenic mediators. These results correspond to findings of immune mediated secondary harm in acute spinal cord injury. Reduced angiogenic activity could be a relevant part of the pathogenesis of DCM and secondary harm to the spinal cord.

Entities:  

Year:  2021        PMID: 33510227     DOI: 10.1038/s41598-021-81766-8

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  71 in total

1.  Approaches to spondylotic cervical myelopathy: conservative versus surgical results in a 3-year follow-up study.

Authors:  Zdenek Kadanka; Miroslav Mares; Josef Bednaník; Vladimír Smrcka; Martin Krbec; Lubor Stejskal; Richard Chaloupka; Dagmar Surelová; Oldrich Novotný; Igor Urbánek; Ladislav Dusek
Journal:  Spine (Phila Pa 1976)       Date:  2002-10-15       Impact factor: 3.468

2.  Human neuropathological and animal model evidence supporting a role for Fas-mediated apoptosis and inflammation in cervical spondylotic myelopathy.

Authors:  Wen Ru Yu; Tianyi Liu; Tim-Rasmus Kiehl; Michael G Fehlings
Journal:  Brain       Date:  2011-04-13       Impact factor: 13.501

3.  An IL-1 receptor antagonist blocks a morphine-induced attenuation of locomotor recovery after spinal cord injury.

Authors:  Michelle A Hook; Stephanie N Washburn; Georgina Moreno; Sarah A Woller; Denise Puga; Kuan H Lee; James W Grau
Journal:  Brain Behav Immun       Date:  2010-10-23       Impact factor: 7.217

Review 4.  Interleukin-1 and inflammatory neurodegeneration.

Authors:  A Simi; N Tsakiri; P Wang; N J Rothwell
Journal:  Biochem Soc Trans       Date:  2007-11       Impact factor: 5.407

5.  Tight squeeze, slow burn: inflammation and the aetiology of cervical myelopathy.

Authors:  Michael S Beattie; Geoffrey T Manley
Journal:  Brain       Date:  2011-05       Impact factor: 13.501

6.  Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia.

Authors:  J K Harrison; Y Jiang; S Chen; Y Xia; D Maciejewski; R K McNamara; W J Streit; M N Salafranca; S Adhikari; D A Thompson; P Botti; K B Bacon; L Feng
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-01       Impact factor: 11.205

Review 7.  Pathophysiology and natural history of cervical spondylotic myelopathy.

Authors:  Spyridon K Karadimas; W Mark Erwin; Claire G Ely; Joseph R Dettori; Michael G Fehlings
Journal:  Spine (Phila Pa 1976)       Date:  2013-10-15       Impact factor: 3.468

8.  Myelopathy and spinal deformity: relevance of spinal alignment in planning surgical intervention for degenerative cervical myelopathy.

Authors:  Mohammed F Shamji; Christopher P Ames; Justin S Smith; John M Rhee; Jens R Chapman; Michael G Fehlings
Journal:  Spine (Phila Pa 1976)       Date:  2013-10-15       Impact factor: 3.468

9.  A novel experimental model of cervical spondylotic myelopathy (CSM) to facilitate translational research.

Authors:  Spyridon K Karadimas; Eun Su Moon; Wen-Ru Yu; Kajana Satkunendrarajah; Joannis K Kallitsis; Georgios Gatzounis; Michael G Fehlings
Journal:  Neurobiol Dis       Date:  2013-03-04       Impact factor: 5.996

Review 10.  Pathobiology of cervical spondylotic myelopathy.

Authors:  Spyridon K Karadimas; Georgios Gatzounis; Michael G Fehlings
Journal:  Eur Spine J       Date:  2014-03-14       Impact factor: 3.134

View more
  2 in total

1.  Potential benefit of olive leaf extract in cervical spondylotic myelopathy model.

Authors:  Sabri Ibrahim; Iqbal Fahlevi Adeputra Nasution; Mahyu Danil; Wismaji Sadewo; Tri Widyawati; Putri Chairani Eyanoer; Kiking Ritarwan; Wibi Riawan; Ridha Darmajaya
Journal:  Ann Med Surg (Lond)       Date:  2021-11-11

2.  Knockdown of miR-372-3p Inhibits the Development of Diabetic Cardiomyopathy by Accelerating Angiogenesis via Activating the PI3K/AKT/mTOR/HIF-1α Signaling Pathway and Suppressing Oxidative Stress.

Authors:  Zhimin Han; Danyang Zhao; Mengfan Han; Rongjin Zhang; Yongmei Hao
Journal:  Oxid Med Cell Longev       Date:  2022-09-16       Impact factor: 7.310

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.